662 reports of this reaction
1.6% of all CALCITRIOL CAPSULES 0.5 MCG reports
#20 most reported adverse reaction
HYPOCALCAEMIA is the #20 most commonly reported adverse reaction for CALCITRIOL CAPSULES 0.5 MCG, manufactured by Strides Pharma Science Limited. There are 662 FDA adverse event reports linking CALCITRIOL CAPSULES 0.5 MCG to HYPOCALCAEMIA. This represents approximately 1.6% of all 42,159 adverse event reports for this drug.
Patients taking CALCITRIOL CAPSULES 0.5 MCG who experience hypocalcaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOCALCAEMIA is a less commonly reported adverse event for CALCITRIOL CAPSULES 0.5 MCG, but still significant enough to appear in the safety profile.
In addition to hypocalcaemia, the following adverse reactions have been reported for CALCITRIOL CAPSULES 0.5 MCG:
The following drugs have also been linked to hypocalcaemia in FDA adverse event reports:
HYPOCALCAEMIA has been reported as an adverse event in 662 FDA reports for CALCITRIOL CAPSULES 0.5 MCG. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOCALCAEMIA accounts for approximately 1.6% of all adverse event reports for CALCITRIOL CAPSULES 0.5 MCG, making it a notable side effect.
If you experience hypocalcaemia while taking CALCITRIOL CAPSULES 0.5 MCG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.